Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Apr 26, 2023 3:06pm

119 Views

Post# 35415303

RE:RE:RE:ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

Jimsenior,<br /> <br /> ONCY said they do not want to do that. They indicated they saw less risk (and obviously less complexity and management) with one partner rather than two.<br /> <br /> One might well pay more than two together. One could own the fundamental intellectual property if they bought us rather than having it parcelled out. 

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta